ALDX
Price:
$4.85
Market Cap:
$288.82M
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for ...[Read more]
Industry
Biotechnology
IPO Date
2014-05-02
Stock Exchange
NASDAQ
Ticker
ALDX
According to Aldeyra Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 276.31M. This represents a change of 52.63% compared to the average of 181.03M of the last 4 quarters.
The mean historical Enterprise Value of Aldeyra Therapeutics, Inc. over the last ten years is 99.62M. The current 276.31M Enterprise Value has changed 27.64% with respect to the historical average. Over the past ten years (40 quarters), ALDX's Enterprise Value was at its highest in in the March 2023 quarter at 434.88M. The Enterprise Value was at its lowest in in the December 2021 quarter at 18.14M.
Average
99.62M
Median
84.65M
Minimum
2.24M
Maximum
278.17M
Discovering the peaks and valleys of Aldeyra Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 12.34%
Maximum Annual Enterprise Value = 278.17M
Minimum Annual Increase = -98.69%
Minimum Annual Enterprise Value = 2.24M
Year | Enterprise Value | Change |
---|---|---|
2023 | 79.72M | -71.34% |
2022 | 278.17M | 12.34% |
2021 | 2.24M | -98.69% |
2020 | 170.48M | 33.34% |
2019 | 127.85M | -3.61% |
2018 | 132.63M | 48.06% |
2017 | 89.58M | 79.04% |
2016 | 50.04M | 10.75% |
2015 | 45.18M | 122.63% |
2014 | 20.29M | 5.43% |
The current Enterprise Value of Aldeyra Therapeutics, Inc. (ALDX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
120.04M
5-year avg
131.69M
10-year avg
99.62M
Aldeyra Therapeutics, Inc.’s Enterprise Value is less than Tarsus Pharmaceuticals, Inc. (1.74B), greater than LianBio (-66141903.00), less than Travere Therapeutics, Inc. (1.95B), greater than Eton Pharmaceuticals, Inc. (270.01M), less than Viridian Therapeutics, Inc. (1.42B), greater than Terns Pharmaceuticals, Inc. (222.97M), less than Structure Therapeutics Inc. (1.75B), less than Blueprint Medicines Corporation (6.36B), less than 89bio, Inc. (940.63M), greater than X4 Pharmaceuticals, Inc. (38.44M), greater than Inozyme Pharma, Inc. (202.73M), less than Day One Biopharmaceuticals, Inc. (963.46M), greater than HOOKIPA Pharma Inc. (-36166707.00), less than Phathom Pharmaceuticals, Inc. (480.38M), greater than Lyra Therapeutics, Inc. (23.90M), less than Cullinan Oncology, Inc. (630.54M), greater than BioLineRx Ltd. (59.94M), less than Ardelyx, Inc. (1.31B), less than Lexicon Pharmaceuticals, Inc. (377.46M), greater than Seres Therapeutics, Inc. (158.02M), less than ImmunityBio, Inc. (4.07B),
Company | Enterprise Value | Market cap |
---|---|---|
1.74B | $1.84B | |
-66141903.00 | $34.47M | |
1.95B | $1.59B | |
270.01M | $290.14M | |
1.42B | $1.60B | |
222.97M | $491.80M | |
1.75B | $1.91B | |
6.36B | $5.98B | |
940.63M | $1.03B | |
38.44M | $57.64M | |
202.73M | $180.51M | |
963.46M | $1.38B | |
-36166707.00 | $20.76M | |
480.38M | $638.64M | |
23.90M | $12.37M | |
630.54M | $730.17M | |
59.94M | $38.31M | |
1.31B | $1.26B | |
377.46M | $312.11M | |
158.02M | $131.23M | |
4.07B | $3.55B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aldeyra Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aldeyra Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Aldeyra Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Aldeyra Therapeutics, Inc. (ALDX)?
What is the 3-year average Enterprise Value for Aldeyra Therapeutics, Inc. (ALDX)?
What is the 5-year average Enterprise Value for Aldeyra Therapeutics, Inc. (ALDX)?
How does the current Enterprise Value for Aldeyra Therapeutics, Inc. (ALDX) compare to its historical average?